5-Fluorouracil in colorectal cancer, a never ending story

Free article

Editorial

R Herrmann. Ann Oncol. 1996 Aug.

Free article

. 1996 Aug;7(6):551-2.

doi: 10.1093/oxfordjournals.annonc.a010668.

No abstract available

Comment in

Role of interferon as a modulator of fluoropyrimidines: reply to a recent editorial.
Wadler S, Schwartz EL. Wadler S, et al. Ann Oncol. 1997 Feb;8(2):139-40; discussion 141. doi: 10.1023/a:1008202826522. Ann Oncol. 1997. PMID: 9093721 No abstract available.
5-Fluorouracil-based treatment of patients with advanced colorectal carcinoma outside clinical trials: importance of limited toxicity.
van Halteren HK, Keuning JJ, Vreugdenhil G. van Halteren HK, et al. Ann Oncol. 1997 Feb;8(2):203. doi: 10.1093/oxfordjournals.annonc.a010860. Ann Oncol. 1997. PMID: 9093734 No abstract available.
5-Fluorouracil revisited: a new perspective for treatment planning.
Presant CA, Wolf W, Waluch V. Presant CA, et al. Ann Oncol. 1997 Feb;8(2):203-4. doi: 10.1093/oxfordjournals.annonc.a010861. Ann Oncol. 1997. PMID: 9093735 No abstract available.

5-Fluorouracil versus 5-fluorouracil plus alpha-interferon as treatment of metastatic colorectal carcinoma. A randomized study.
Dufour P, Husseini F, Dreyfus B, Cure H, Martin C, Prevost G, Olivier JP, Dumas F, Duclos B, Olivares R, Leszler A, Bergerat JP, Audhuy B, Thill L, Oberling F. Dufour P, et al. Ann Oncol. 1996 Aug;7(6):575-9. doi: 10.1093/oxfordjournals.annonc.a010673. Ann Oncol. 1996. PMID: 8879370 Clinical Trial.